Ebselen for Moderate COVID-19

Palo Alto (17 mi)

Overseen byHaifan Lin, PhD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Sound Pharmaceuticals, Incorporated

Prior Safety Data

Trial Summary

What is the purpose of this trial?The study is a randomized, double-blind, placebo-controlled, dose escalation, multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID-19 disease.

Eligibility Criteria

This trial is for adults over 18 with moderate COVID-19 symptoms, confirmed by a positive PCR test. They must be in-patients and have had symptoms for ≤3 days before joining the study. Pregnant or breastfeeding women, those with liver/kidney issues, or participation in another drug/device study within 30 days are excluded.

Treatment Details

The trial tests SPI-1005 (Ebselen) against a placebo to see if it helps patients with moderate COVID-19. It's randomized and double-blind, meaning neither the researchers nor participants know who gets the real treatment versus placebo until after results are collected.

3Treatment groups

Experimental Treatment

Placebo Group

Group I: SPI-1005 800 mg BIDExperimental Treatment1 Intervention

Oral administration of SPI-1005 800 mg BID for 7 days, with 30-day follow-up

Group II: SPI-1005 400 mg BIDExperimental Treatment1 Intervention

Oral administration of SPI-1005 400 mg BID for 7 days, with 30-day follow-up

Group III: PlaceboPlacebo Group1 Intervention

Oral administration of matching placebo BID for 7 days, with 30-day follow-up